Cost-effectiveness of continuous erythropoietin receptor activator in anemia

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, July 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

policy: 2 policy sources

twitter: 3 X users

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 30 Mendeley

Summary Policy documents X Dimensions citations

So far, Dimensions has found 13 publications that cite this research output.

13

The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.

Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis

Article in Renal Failure (February 2024)

Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail

Article in Chronic Diseases and Translational Medicine (March 2022)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients

Article in Cureus (December 2020)